Intermediate metabolites of the cholesterol synthesis pathway, including mevalonate, isoprenoids, and sterols (65), closely relate to the progression of cancer
MLT act as potent antioxidant agent by direct scavenging of free radicals in mitochondria and the stimulation of the gene expression of multiple antioxidant enzymes including SODs, CAT, GPx, and GRd etc
Pharmacokinetic studies demonstrate that LCT reaches peak plasma concentrations much faster than standard free-base carnitine, making it highly effective for quickly delivering metabolic support to skeletal muscles
Most clinical guidance supports treatment for at least 12 months, with ongoing therapy recommended for patients who respond well and have no significant side effects
Experimental studies also support mitochondrial transfer or mitochondrial-support signaling as a contributor to recovery [31,32,33,34,35]